Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Notes Payables (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Notes Payables for 12 consecutive years, with $183650.0 as the latest value for Q4 2025.

  • On a quarterly basis, Notes Payables rose 7.72% to $183650.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $183650.0, a 7.72% increase, with the full-year FY2025 number at $183650.0, up 7.72% from a year prior.
  • Notes Payables was $183650.0 for Q4 2025 at Cryo Cell International, up from $179187.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $3.1 million in Q1 2021 to a low of $150527.0 in Q4 2022.
  • A 5-year average of $730177.8 and a median of $176095.0 in 2024 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: tumbled 94.21% in 2022, then increased 10.04% in 2023.
  • Cryo Cell International's Notes Payables stood at $1.9 million in 2021, then tumbled by 92.07% to $150527.0 in 2022, then rose by 10.04% to $165641.0 in 2023, then grew by 2.93% to $170488.0 in 2024, then grew by 7.72% to $183650.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Notes Payables are $183650.0 (Q4 2025), $179187.0 (Q3 2025), and $177603.0 (Q2 2025).